PL4094763T3 - Związek do stosowania w zapobieganiu i/lub leczeniu stanu wywołanego lub związanego z koronawirusem - Google Patents

Związek do stosowania w zapobieganiu i/lub leczeniu stanu wywołanego lub związanego z koronawirusem

Info

Publication number
PL4094763T3
PL4094763T3 PL21827086.6T PL21827086T PL4094763T3 PL 4094763 T3 PL4094763 T3 PL 4094763T3 PL 21827086 T PL21827086 T PL 21827086T PL 4094763 T3 PL4094763 T3 PL 4094763T3
Authority
PL
Poland
Prior art keywords
coronavirus
prevention
compound
treatment
condition caused
Prior art date
Application number
PL21827086.6T
Other languages
English (en)
Inventor
Di KANG
Danni LI
Xingyu LIN
Tingting Lu
Original Assignee
Felicamed Biotechnology Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Felicamed Biotechnology Co., Ltd. filed Critical Felicamed Biotechnology Co., Ltd.
Publication of PL4094763T3 publication Critical patent/PL4094763T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL21827086.6T 2020-06-16 2021-06-11 Związek do stosowania w zapobieganiu i/lub leczeniu stanu wywołanego lub związanego z koronawirusem PL4094763T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010547186.8A CN113797198B (zh) 2020-06-16 2020-06-16 一种化合物在预防和/或治疗动物的病原体感染中的应用
PCT/CN2021/099650 WO2021254265A1 (zh) 2020-06-16 2021-06-11 一种化合物在预防和/或治疗动物的病原体感染中的应用

Publications (1)

Publication Number Publication Date
PL4094763T3 true PL4094763T3 (pl) 2025-02-17

Family

ID=78892522

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21827086.6T PL4094763T3 (pl) 2020-06-16 2021-06-11 Związek do stosowania w zapobieganiu i/lub leczeniu stanu wywołanego lub związanego z koronawirusem

Country Status (14)

Country Link
US (1) US20230097009A1 (pl)
EP (1) EP4094763B1 (pl)
JP (1) JP7442662B2 (pl)
KR (1) KR102967689B1 (pl)
CN (2) CN113797198B (pl)
AU (1) AU2021291983B2 (pl)
BR (1) BR112022016727A2 (pl)
CO (1) CO2022011666A2 (pl)
ES (1) ES2990998T3 (pl)
MX (1) MX2022010020A (pl)
PH (1) PH12022552166A1 (pl)
PL (1) PL4094763T3 (pl)
WO (1) WO2021254265A1 (pl)
ZA (1) ZA202213500B (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113797202B (zh) * 2020-06-16 2024-06-28 珠海宇繁生物科技有限责任公司 Hpk1激酶抑制剂在预防和/或治疗动物的病原体感染中的应用
CN114437058B (zh) * 2020-10-30 2026-07-24 广州宇繁南图生物科技有限公司 氘代hpk1激酶抑制剂及其制备方法和应用
CN116535422B (zh) * 2022-01-26 2025-04-18 上海交通大学 具有五元芳杂环并哌啶/高哌啶的hpk1抑制剂及其制备方法及用途
CN114839378B (zh) * 2022-07-04 2022-09-06 山东康华生物医疗科技股份有限公司 一种猫疱疹和猫杯状病毒联合检测试剂盒
CN114966020B (zh) * 2022-07-13 2022-09-27 北京市农林科学院 检测牛传染性鼻气管炎病毒的胶体金试纸条及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019090198A1 (en) * 2017-11-06 2019-05-09 Bristol-Myers Squibb Company Isofuranone compounds useful as hpk1 inhibitors
CN110372664A (zh) * 2018-04-13 2019-10-25 华东理工大学 选择性jak2抑制剂及其应用
CN110396087A (zh) * 2018-04-25 2019-11-01 珠海宇繁生物科技有限责任公司 Hpk1激酶抑制剂、制备方法及其应用
WO2019206049A1 (en) * 2018-04-25 2019-10-31 Zhuhai Yufan Biotechnologies Co., Ltd Hpk1 inhibitors, preparation method and application thereof
BR112020023359A2 (pt) * 2018-05-15 2021-02-09 Erasmus University Medical Center Rotterdam tratamentos e biomarcadores para o prognóstico de infecção pelo vírus zika
EP3873608A1 (en) * 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
CN110063954B (zh) * 2019-04-10 2021-08-06 华中农业大学 Fhpi在制备治疗猫传染性腹膜炎药物中的应用
CN110215456A (zh) * 2019-06-25 2019-09-10 华中农业大学 一种由gc376与gs-441524组成的猫冠状病毒抑制剂组合物
CN113797202B (zh) * 2020-06-16 2024-06-28 珠海宇繁生物科技有限责任公司 Hpk1激酶抑制剂在预防和/或治疗动物的病原体感染中的应用

Also Published As

Publication number Publication date
EP4094763B1 (en) 2024-09-18
ZA202213500B (en) 2023-07-26
PH12022552166A1 (en) 2023-11-29
KR20220129592A (ko) 2022-09-23
CN117338775A (zh) 2024-01-05
EP4094763A1 (en) 2022-11-30
CN113797198B (zh) 2023-11-28
CO2022011666A2 (es) 2022-08-30
CN113797198A (zh) 2021-12-17
BR112022016727A2 (pt) 2022-12-27
JP2023525430A (ja) 2023-06-16
WO2021254265A1 (zh) 2021-12-23
ES2990998T3 (es) 2024-12-02
US20230097009A1 (en) 2023-03-30
AU2021291983A1 (en) 2022-09-08
CA3168377A1 (en) 2021-12-23
JP7442662B2 (ja) 2024-03-04
MX2022010020A (es) 2022-10-10
EP4094763A4 (en) 2023-04-26
NZ791250A (en) 2025-05-02
AU2021291983B2 (en) 2024-01-18
EP4094763C0 (en) 2024-09-18
KR102967689B1 (ko) 2026-05-21

Similar Documents

Publication Publication Date Title
GB2590793B (en) Cannabidiol-C1 for use as a medicament and in the treatment of epilepsy
GB202014723D0 (en) Use of cannabinoids in the treatment of epilepsy
ZA202307970B (en) Compounds for use in the treatment and prevention of covid- 19
GB202003059D0 (en) Compounds for use in a method of treating, preventing and/or reducing the symptoms of pain
IL277315B (en) Method and preparations for treating the corona virus infection
GB202100635D0 (en) Compounds and methods for treating or preventing dirofilaria infection in a mammal
GB202416046D0 (en) Compounds of use in methods for the treatment or prohylaxis of a coronavirus infection or covid 19
IL280475B2 (en) Pharmaceutical preparation for use in the treatment or prevention of a C5-related disease and a method for treating or preventing a C5-related disease
EP4094763C0 (en) COMPOUND FOR USE IN THE PREVENTION AND/OR TREATMENT OF A CONDITION CAUSED BY OR ASSOCIATED WITH A CORONAVIRUS
GB202108690D0 (en) Use of cannabinoids in the treatment of epilepsy
EP4385576A3 (en) Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension
IL309002A (en) Compounds useful in the treatment or prevention of a PRMT5-mediated disorder
GB202103578D0 (en) Prevention and treatment of infections including those caused by coronavirus
IL309243A (en) Radioimmunoconjugates and combination therapy with barrier surveillance
ZA202210111B (en) Anti-coronavirus effect and application of pi4k inhibitor
IL321017A (en) Inhibitors and/or decomposers containing 3-fluoro-4-hydroxybenzmide and uses thereof
TN2011000366A1 (en) Use of deferiprone for treatment and prevention of iron-related eye dosorders
IL316132A (en) Cannabidiol for the prevention and treatment of interferon-responsive conditions
PL4346847T3 (pl) Kompleks wielojonowy do stosowania w profilaktyce lub leczeniu zapalenia neurogennego
ZA202210311B (en) Coronavirus therapeutics and treatment methods
GB202008250D0 (en) Diagnosis, prevention and treatment of coronavirus infection
HUE059233T2 (hu) Vegyület epizootius nyúl-enteropátia kezelésében és/vagy megelõzésében való alkalmazásra
GB2610895B (en) Composition for use in the treatment and/or prevention of mycotoxic disease
GB202109590D0 (en) Combination treatment for coronavirus
GB202017580D0 (en) Reduction and/or prevention of infection in a subject